Patterns in admission delays to outpatient methadone treatment in the United States

Journal of Substance Abuse Treatment

Volumn 41, Issue 4, 2011, Pages 431-439

  Gryczynski, Jan ^a   Schwartz, Robert P ^a   Salkever, David S ^b   Mitchell, Shannon Gwin ^a   Jaffe, Jerome H ^a  

^a FRIENDS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

Admission delays; Disparities; Methadone; Program capacity; Treatment access; Waiting lists

Indexed keywords

ALCOHOL; DIAMORPHINE; METHADONE; OPIATE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; COCAINE DEPENDENCE; COMORBIDITY; CRIMINAL JUSTICE; DRUG ABUSE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; ETHNIC GROUP; FEMALE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEROIN DEPENDENCE; HOSPITAL ADMISSION; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METHADONE TREATMENT; MINORITY GROUP; OPIATE ADDICTION; OUTPATIENT; OUTPATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; SUBSTANCE ABUSE; UNITED STATES;

ADULT; AMBULATORY CARE; ANALGESICS, OPIOID; CONTINENTAL POPULATION GROUPS; DATABASES, FACTUAL; ETHNIC GROUPS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; METHADONE; MINORITY GROUPS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OUTPATIENTS; PATIENT ADMISSION; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE TREATMENT CENTERS; UNITED STATES;

EID: 82455210920     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2011.06.005     Document Type: Article

References (61)

1. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 2005, 28:321-329.
2. Anglin M.D., Hser Y.I., Grella C.E. Drug addiction and treatment careers among clients in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors 1997, 11:308-323.
3. Appel P.W., Ellison A.A., Jansky H.K., Oldak R. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: Opinions of drug injecting street outreach clients and other system stakeholders. American Journal of Drug and Alcohol Abuse 2004, 30:129-153.
4. Barnett P.G., Hui S.S. The cost-effectiveness of methadone maintenance. The Mount Sinai Journal of Medicine 2000, 67:365-374.
5. Bell J., Caplehorn J.R.M., McNeil D.R. The effect of intake procedures on performance in methadone maintenance. Addiction 1994, 89:463-471.
6. Booth R.E., Corsi K.F., Mikulich S.K. Improving entry to methadone maintenance among out-of-treatment injection drug users. Journal of Substance Abuse Treatment 2003, 24:305-311.
7. Booth R.E., Kwiatkowski C., Iguchi M.Y., Pinto F., John D. Facilitating treatment entry among out-of-treatment injection drug users. Public Health Reports 1998, 113(Suppl1):116-128.
8. Carise D., McLellan A.T., Gifford L.S., Kleber H.D. Developing a national addiction treatment information system: An introduction to the Drug Evaluation Network System. Journal of Substance Abuse Treatment 1999, 17:67-77.
9. Carr C.J., Xu J., Redko C., Lane D.T., Rapp R.C., Goris J., et al. Individual and system influences on waiting time for substance abuse treatment. Journal of Substance Abuse Treatment 2008, 34:192-201.
10. Chun J.S., Guydish J.R., Silber E., Gleghorn A. Drug treatment outcomes for persons on waiting lists. The American Journal of Drug and Alcohol Abuse 2008, 34:526-533.
11. Clarke P. When can group level clustering be ignored? Multilevel models versus single-level models with sparse data. Journal of Epidemiology & Community Health 2008, 62:752-758.
12. Code of Federal Regulations. Capacity of treatment for intravenous substance abusers (Title 45, Code of Federal Regulations, Part 96, Section 96.126). Washington, DC: Department of Health and Human Services.
13. Coffey R.M., Levit K.R., Kassed C.A., McLellan A.T., Chalk M., Brady T.M., et al. Evidence for substance abuse services and policy research. A systematic review of national databases. Evaluation Review 2009, 33:103-137.
14. Comer S.D., Sullivan M.A., Hulse G.K. Sustained-release naltrexone: Novel treatment for opioid dependence. Expert Opinion on Investigational Drugs 2007, 16:1285-1294.
15. Cooper J.R. Methadone treatment and acquired immunodeficiency syndrome. Journal of the American Medical Association 1989, 262:1664-1668.
16. Corsi K.F., Kwiatkowski C.F., Booth R.E. Treatment entry and predictors among opiate-using injection drug users. American Journal of Drug and Alcohol Abuse 2007, 33:121-127.
17. Coviello D.M., Zanis D.A., Wesnoski S.A., Alterman A.I. The effectiveness of outreach case management in re-enrolling discharged methadone patients. Drug and Alcohol Dependence 2006, 85:56-65.
18. Craddock S.G., Rounds-Bryant J.L., Flynn P.M., Hubbard R.L. Characteristics and pretreatment behaviors of clients entering drug abuse treatment: 1969-1993. American Journal of Drug and Alcohol Abuse 1997, 23:43-59.
19. Darke S., Hall W. Heroin overdose: Research and evidence-based intervention. Journal of Urban Health 2003, 80:189-200.
20. Davey M.A., Latkin C.A., Hua W., Tobin K.E., Strathdee S. Individual and social network factors that predict entry to drug treatment. American Journal on Addictions 2007, 16:38-45.
21. Des Jarlais D.C., Paone D., Friedman S.R., Peyser N., Newman R.G. Regulating controversial programs for unpopular people: Methadone maintenance and syringe exchange programs. American Journal of Public Health 1995, 85:1577-1584.
22. Donovan D.M., Rosengren D.B., Downey L., Cox G.B., Sloan K.L. Attrition prevention with individuals awaiting publicly funded drug treatment. Addiction 2001, 96:1149-1160.
23. Festinger D.S., Lamb R.J., Kountz M.R., Kirby K.C., Marlowe D. Pretreatment dropout as a function of treatment delay and client variables. Addictive Behaviors 1995, 20:111-115.
24. Fletcher B.W., Tims F.M., Brown B.S. Drug Abuse Treatment Outcome Study (DATOS): Treatment evaluation research in the United States. Psychology of Addictive Behaviors 1997, 11:216-229.
25. Friedmann P.D., Lemon S.C., Stein M.D., D'Aunno T.A. Accessibility of addiction treatment: Results from a national survey of outpatient substance abuse treatment organizations. Health Services Research 2003, 38:887-903.
26. General Accounting Office Some clinics not meeting goal of prompt treatment for intravenous drug users. (gao/hrd-90-80br) 1990, General Accounting Office, Washington, DC.
27. Gibson D.R., Flynn N.M., McCarthy J.J. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999, 13:1807-1818.
28. Glasscote R., Sussex J.N., Jaffe J.H., Ball J., Brill L. The treatment of drug abuse: Programs, problems, prospects 1972, 127-151. Joint Information Service of the American Psychiatric Association and the National Association for Mental Health, Washington, DC.
29. Gryczynski J., Schwartz R., O'Grady K., Jaffe J. Treatment entry among individuals on a waiting list for methadone maintenance. American Journal of Drug and Alcohol Abuse 2009, 35:290-294.
30. Hser Y.I., Hoffman V., Grella C.E., Anglin M.D. A 33-year follow-up of narcotics addicts. Archives of General Psychiatry 2001, 58:503-508.
31. Hser Y.I., Maglione M., Polinsky M.L., Anglin M.D. Predicting drug treatment entry among treatment-seeking individuals. Journal of Substance Abuse Treatment 1998, 15:213-220.
32. Inter-University Consortium for Political and Social Research, I Treatment Episode Data Set (TEDS), 2006. [Codebook; ICPSR No. 21540] 2008, ICPSR, Ann Arbor, MI.
33. Inter-University Consortium for Political and Social Research, I National Survey of Substance Abuse Treatment Services (N-SSATS), 2006. [Codebook; ICPSR No. 20004] 2008, ICPSR, Ann Arbor, MI.
34. Lewis D.C. Access to narcotic addiction treatment and medical care: Prospects for the expansion of methadone maintenance treatment. Journal of Addictive Diseases 1999, 18:5-21.
35. Ling W., Casadonte P., Bigelow G., Kampman K.M., Patkar A., Bailey G.L., et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. Journal of the American Medical Association 2010, 304:1576-1583.
36. Mark T.L., Woody G.E., Juday T., Kleber H.D. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence 2001, 61:195-206.
37. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction 2002, 93:515-532.
38. Maryland Department of Health and Mental Hygiene Plan to expand access to substance abuse services in Maryland by 25% by 2012 Retrieved November 1, 2010, from. http://www.statestat.maryland.gov/GDU/15SubstanceAbuseDeliveryPlan.pdf.
39. McAuliffe W.E., Dunn R. Substance abuse treatment needs and access in the USA: Interstate variations. Addiction 2004, 99:999-1014.
40. McCarty D., Gustafson D., Capoccia V.A., Cotter F. Improving care for the treatment of alcohol and drug disorders. Journal of Behavioral Health Services Research 2009, 36:52-60.
41. McCaughrin W.C., Howard D.L. Variation in access to outpatient substance abuse treatment: Organizational factors and conceptual issues. Journal of Substance Abuse 1996, 8:403-415.
42. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndrome 1993, 6:1049-1056.
43. Moineddin R., Matheson F.I., Glazier R.H. A simulation study of sample size for multilevel logistic regression. BMC Medical Research Methodology 2007, 7:34.
44. Consensus Development Panel N.I.H. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Journal of the American Medical Association 1998, 280:1936-1943.
45. Peterson J.A., Schwartz R.P., Mitchell S.G., Reisinger H.S., Kelly S.M., O'Grady K.E., et al. Why don't out-of-treatment individuals enter methadone treatment programs?. International Journal of Drug Policy 2010, 21:36-42.
46. Rapp R.C., Otto A.L., Lane D.T., Redko C., McGatha S., Carlson R.G. Improving linkage with substance abuse treatment using brief case management and motivational interviewing. Drug and Alcohol Dependence 2008, 94:175-182.
47. Redko C., Rapp R.C., Carlson R.G. Waiting time as a barrier to treatment entry: Perceptions of substance users. Journal of Drug Issues 2006, 36:831-852.
48. Schwartz R.P., Highfield D.A., Jaffe J.H., Brady J.V., Butler C.B., Rouse C.O., et al. A randomized controlled trial of interim methadone maintenance. Archives of General Psychiatry 2006, 63:102-109.
49. Schwartz R.P., Jaffe J.H., Highfield D.A., Callaman J.M., O'Grady K.E. A randomized controlled trial of interim methadone maintenance: 10-Month follow-up. Drug and Alcohol Dependence 2007, 86:30-36.
50. Schwartz R.P., Jaffe J.H., O'Grady K.E., Kinlock T.W., Gordon M.S., Kelly S.M., et al. Interim methadone treatment: Impact on arrests. Drug and Alcohol Dependence 2009, 103:148-154.
51. Schwartz, R. P., Kelly, S. M., O'Grady, K. E., Gandhi, D., & Jaffe. J. H. (in press). Interim methadone treatment compared to standard methadone treatment: 4-month findings. Journal of Substance Abuse Treatment.
52. Sorensen J., Masson C., Delucchi K., Sporer K., Barnett P., Mitsuishi F., et al. Randomized trial of drug abuse treatment-linkage strategies. Journal of Consulting and Clinical Psychology 2005, 73:1026-1035.
53. Strathdee S.A., Ricketts E.P., Huettner S., Cornelius L., Bishai D., Havens J.R., et al. Facilitating entry into drug treatment among injecting drug users referred from needle exchange program: Results from a community-based behavioral intervention trial. Drug and Alcohol Dependence 2006, 83:225-232.
54. Substance Abuse and Mental Health Services Administration (SAMHSA) The DASIS report. Treatment Episode Data Set (TEDS) Retrieved April 7, 2009, from. http://www.oas.samhsa.gov/2k2/TEDS/TEDS.pdf.
55. Substance Abuse and Mental Health Services Administration (SAMHSA) Treatment Episode Dataset (TEDS) State Instruction Manual Retrieved August 12, 2010, from. http://wwwdasis.samhsa.gov/dasis2/manuals/teds_adm_manual.pdf.
56. U.S. Census Bureau Data on population characteristics by metropolitan and micropolitan statistical areas. Population estimates division Retrieved March 30, 2009, from. http://www.census.gov/population/www/metroareas/metroarea.html.
57. Warner-Smith M., Darke S., Lynskey M., Hall W. Heroin overdose: Causes and consequences. Addiction 2001, 96:1113-1125.
58. Wilson M.E., Schwartz R.P., O'Grady K.E., Jaffe J.H. Impact of interim methadone maintenance on HIV risk behaviors. Journal of Urban Health 2010, 87:586-591.
59. Yancovitz S.R., Des Jarlais D.C., Peyser N.P., Drew E., Friedmann P., Trigg H.L., et al. A randomized trial of an interim methadone maintenance clinic. American Journal of Public Health 1991, 81:1185-1191.
60. Zaric G.S., Barnett P.G., Brandeau M.L. HIV transmission and the cost-effectiveness of methadone maintenance. American Journal of Public Health 2000, 90:1100-1111.
61. Zaric G.S., Brandeau M.L., Barnett P.G. Methadone maintenance and HIV prevention: A cost-effectiveness analysis. Management Science 2000, 46:1013-1031.